Search

everythinglearnresearchcommunity

for

Search:↓

Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Mycophenolate mofetil was effective for most patients in treating scarring hair loss, but some had side effects.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

Mycophenolate mofetil may safely help restore skin color in depigmentation conditions.

Purpura fulminans can signal underlying autoimmune disorders, not just infections.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Integrin-linked kinase is crucial for normal skin healing.

IL-15 promotes hair growth and protects hair follicles.

Nanomedicine-based immunotherapy shows promise in improving tissue repair and regeneration.

Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.

Immune system failure in hair follicles causes lichen planopilaris, leading to hair loss.

A specific gene mutation causes a rare hair loss condition in a Chinese patient.

A new mouse model for vitiligo helps study immune responses and potential treatments.

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

Anti-CD19 therapy may help treat SLE and NMOSD.

Targeting the HEDGEHOG-GLI1 pathway could help treat keloids.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

A man developed skin lesions as a side effect of a gamma secretase inhibitor used for treating a tumor.

Proinflammatory fibroblasts and vascular endothelial cells are key in keloid development.

Chemotherapy-induced hair loss is partly due to decreased laminin-511 and increased laminin-332.

New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.

IL-9 increases skin cell movement but decreases their ability to invade, and this effect is controlled by cell contractility, not by MMPs.